BAM
AKRO

Belpointe Asset Management’s Akero Therapeutics AKRO Stock Holding History

Belpointe Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,730
Closed -$94.8K – 3724
2022
Q4 		$94.8K Buy
+1,730
New +$74.1K 0.01% 1269
2021
Q4 		– Sell
-21,890
Closed -$489K – 1198
2021
Q3 		$489K Sell
21,890
-190
-0.9% -$4.3K 0.03% 513
2021
Q2 		$548K Hold
22,080
– – 0.04% 469
2021
Q1 		$641K Buy
+22,080
New +$668K 0.05% 344

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Belpointe Asset Management's AKRO Position: Q1 2023 in Review

Belpointe Asset Management sold out of Akero Therapeutics (AKRO) in Q1 2023, closing a stake of 1,730 shares — an estimated $94.8K sold.

Belpointe Asset Management first reported a position in AKRO in Q1 2021 and held it in 4 quarters. The position peaked at $641K in Q1 2021. 156 funds tracked by Wall St. Rank hold AKRO as of Q1 2023.

  • Belpointe Asset Management reported no remaining Akero Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,730 Akero Therapeutics shares in Q1 2023, an estimated $94.8K.
  • Belpointe Asset Management first reported a position in Akero Therapeutics in Q1 2021 and held it in 4 quarters.
  • Belpointe Asset Management's Akero Therapeutics position peaked at $641K in Q1 2021.
  • 156 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.